Compare Biocon with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs LUPIN - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LUPIN BIOCON /
LUPIN
 
P/E (TTM) x 32.9 40.2 81.7% View Chart
P/BV x 3.9 3.7 105.9% View Chart
Dividend Yield % 0.3 0.6 42.9%  

Financials

 BIOCON    LUPIN
EQUITY SHARE DATA
    BIOCON
Mar-19
LUPIN
Mar-20
BIOCON /
LUPIN
5-Yr Chart
Click to enlarge
High Rs707882 80.2%   
Low Rs554505 109.7%   
Sales per share (Unadj.) Rs91.9339.4 27.1%  
Earnings per share (Unadj.) Rs16.7-5.9 -281.0%  
Cash flow per share (Unadj.) Rs24.215.5 156.3%  
Dividends per share (Unadj.) Rs1.006.00 16.7%  
Dividend yield (eoy) %0.20.9 18.3%  
Book value per share (Unadj.) Rs101.6276.7 36.7%  
Shares outstanding (eoy) m600.00453.00 132.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.92.0 335.7%   
Avg P/E ratio x37.7-116.6 -32.4%  
P/CF ratio (eoy) x26.144.8 58.2%  
Price / Book Value ratio x6.22.5 247.5%  
Dividend payout %6.0-100.9 -5.9%   
Avg Mkt Cap Rs m378,330314,201 120.4%   
No. of employees `0006.118.3 33.5%   
Total wages/salary Rs m11,65329,868 39.0%   
Avg. sales/employee Rs Th8,994.38,400.6 107.1%   
Avg. wages/employee Rs Th1,900.71,632.0 116.5%   
Avg. net profit/employee Rs Th1,635.3-147.2 -1,111.0%   
INCOME DATA
Net Sales Rs m55,144153,748 35.9%  
Other income Rs m1,4444,838 29.8%   
Total revenues Rs m56,588158,585 35.7%   
Gross profit Rs m15,88324,849 63.9%  
Depreciation Rs m4,4789,702 46.2%   
Interest Rs m7093,630 19.5%   
Profit before tax Rs m12,14016,355 74.2%   
Minority Interest Rs m94 230.8%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m2,12311,571 18.3%   
Profit after tax Rs m10,026-2,694 -372.2%  
Gross profit margin %28.816.2 178.2%  
Effective tax rate %17.570.8 24.7%   
Net profit margin %18.2-1.8 -1,037.7%  
BALANCE SHEET DATA
Current assets Rs m48,228154,132 31.3%   
Current liabilities Rs m30,37692,252 32.9%   
Net working cap to sales %32.440.2 80.4%  
Current ratio x1.61.7 95.0%  
Inventory Days Days6882 83.2%  
Debtors Days Days86129 66.1%  
Net fixed assets Rs m64,13089,082 72.0%   
Share capital Rs m3,000906 331.1%   
"Free" reserves Rs m57,980124,461 46.6%   
Net worth Rs m60,980125,367 48.6%   
Long term debt Rs m15,76617,933 87.9%   
Total assets Rs m121,924249,839 48.8%  
Interest coverage x18.15.5 329.2%   
Debt to equity ratio x0.30.1 180.7%  
Sales to assets ratio x0.50.6 73.5%   
Return on assets %8.80.4 2,350.4%  
Return on equity %16.4-2.1 -765.1%  
Return on capital %16.88.7 192.0%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50651,450 30.1%   
Fx outflow Rs m10,39919,470 53.4%   
Net fx Rs m5,10731,980 16.0%   
CASH FLOW
From Operations Rs m11,54614,688 78.6%  
From Investments Rs m-7,13811,070 -64.5%  
From Financial Activity Rs m-2,417-8,906 27.1%  
Net Cashflow Rs m2,10316,853 12.5%  

Share Holding

Indian Promoters % 40.4 46.6 86.7%  
Foreign collaborators % 20.6 0.2 10,300.0%  
Indian inst/Mut Fund % 8.4 11.3 74.3%  
FIIs % 10.7 31.9 33.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.1 197.0%  
Shareholders   109,995 98,259 111.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   NATCO PHARMA  PANACEA BIOTECH  FDC  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Feb 25, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS